Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.

Yıldız, İbrahim; Ekenel, Meltem; Akman, Tülay; Kocar, Muharrem; Uysal, Mükremın; Kanıtez, Metin; Bayoğlu, Vedat; Varol, Umut; Tural, Deniz; Avcı, Nilüfer; Kaplan, Muhammet Ali; Surmeli, Zeki Gokhan; Dede, İsa; Ulaş, Arife; Yazıcı, Ozan; Başaran, Mert

doi:10.1200/jco.2014.32.15_suppl.e15602

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yildiz et al . evaluated 63 nccRCC patients, and the ORR was 11.1% and the disease control rate was 63.5% with a median PFS and OS of 7.6 and 22.0 months, respectively …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma

Shi

Tian

2015

Asia‐Pac J Clin Oncol

View full text Add to dashboard Cite

Aim: This study evaluated the safety and efficacy of sunitinib in the treatment of advanced non-clear cell renal cell carcinoma. Methods: Thirty-seven Chinese patients with advanced non-clear cell renal cell carcinoma were enrolled from October 2008 to October 2013. Sunitinib monotherapy was administered in repeated 6-week cycles of daily oral administration of 50 mg for 4 weeks, followed by 2 weeks off. Computed tomography scan was used to evaluate the efficacy every two cycles. Results: All 37 patients received sunitinib treatment according to the schedule and were evaluated for response and toxicity. Thirty (81.1%) patients underwent nephrectomy before sunitinib treatment and seven (18.9%) patients had kidney biopsy. Twenty-five patients were diagnosed with papillary renal cell carcinoma, two with spindle cell-type renal cell carcinoma, two with chromophobe renal cell carcinoma and eight with unclassified cell types. The disease control rate was 73.0%, with partial response in 5 (13.5%), stable disease in 22 (59.5%) and progression disease in 10 (27.0%), the best tumor response. The median progression-free survival (PFS) was 6 months and the median overall survival (OS) was 9 months. In patients with papillary renal cell carcinoma, the median PFS was 6 months and the median OS was 10 months. The most common adverse events were hand-foot syndrome, fatigue, leukopenia, anemia, thrombocytopenia, mucositis, edema and hypertension. All adverse events were ameliorated by supportive treatment, dose reduction or treatment interruption. Conclusion: Sunitinib was efficacious in the treatment of advanced non-clear cell renal cell carcinoma. Most adverse events were tolerable.

show abstract

“…Yildiz et al . evaluated 63 nccRCC patients, and the ORR was 11.1% and the disease control rate was 63.5% with a median PFS and OS of 7.6 and 22.0 months, respectively …”

Section: Discussionmentioning

confidence: 99%

“…Most of the phase III clinical trials in RCC have restricted enrollment to patients with the clear cell subtype. Only a few phase II clinical trials and retrospective studies have focused on nccRCC . The efficacy of sunitinib for non‐clear cell subtypes remains poorly documented.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma

Shi

Tian

2015

Asia‐Pac J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…In contrast to clear cell RCC, the evidence for sunitinib treatment in non-clear cell RCC is less strong, as most of the phase III trials in RCC have restricted the enrolment to patients whose tumours are of clear cell subtype. Data are available from several retrospective and prospective phase II trials, which have focused on non-clear cell RCC histology, as well as from a subgroup analyses of the large EAP [Choueiri et al 2008;Yildiz et al 2014;Paglino et al 2012;Shi et al 2015;Molina et al 2012a;Tannir et al 2012;Ravaud et al 2015;Lee et al 2012;Gore et al 2015].…”

Section: Sunitinib and Non-clear Cell Renal Cancermentioning

confidence: 99%

“…Data are available from several retrospective and prospective phase II trials, which have focused on non-clear cell RCC histology, as well as from a subgroup analyses of the large EAP [Choueiri et al . 2008; Yildiz et al . 2014; Paglino et al .…”

Section: Sunitinib and Non-clear Cell Renal Cancermentioning

confidence: 99%

Sunitinib in the treatment of metastatic renal cell carcinoma

Schmid

Gore

2016

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy. Sunitinib alone causes significant side effects and has a distinct profile with diarrhoea, hypertension, skin effects hypothyroidism, fatigue and nausea of special interest. The recommended dose of sunitinib in mRCC is 50 mg orally daily for 4 weeks, followed by 2 weeks off treatment (4/2 schedule). An alternative 2 weeks on, 1 week off schedule (2/1 schedule) seems to be of similar efficacy and better tolerability and could be more widely used in the future. An intermittent treatment strategy with a stop in remission and re-induction after progression showed efficacy in smaller trials and is currently being evaluated in a phase III trial. Direct comparison of sunitinib with pazopanib in first-line treatment showed a similar efficacy for both TKIs with a distinct toxicity profile. Data from two phase II trials showed that sunitinib has also activity in non-clear cell cancer and is an option due to a lack of better alternatives. Currently, after immune checkpoint inhibitors have shown very promising results in the second-line treatment of RCC, they are being tested in a number of phase III trials in the first-line setting. The future will show the position of sunitinib in the first-line treatment of RCC in the era of the immune checkpoint inhibitors.

show abstract

“…These three studies included fifty three [18], sixty three [29] and twenty one [31] patients. • Two retrospective studies involving sunitinib treatment for papillary RCC only.…”

Section: Retrospective Studiesmentioning

confidence: 99%

Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): A systematic review of the literature

Abdel‐Rahman

Fouad

2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.

Cited by 3 publications

References 0 publications

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma

Sunitinib in the treatment of metastatic renal cell carcinoma

Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): A systematic review of the literature

Contact Info

Product

Resources

About